{"entity":{"id":"nct02444819","kind":"trial","name":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","aka":[],"tldr":"A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, completed.","summary":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy is a phase 2 interventional study registered as NCT02444819 by Hanmi Pharmaceutical Company Limited, with 33 participants recorded, started 2015-03 and reaching its primary completion in 2017-08. Interventions recorded: HM61713. Conditions recorded: Non Small Cell Lung Cancer.\n\nLinked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02444819","url":"https://clinicaltrials.gov/study/NCT02444819"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["olmutinib"],"companies":["hanmi-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02444819","phase":"2","setting":"A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation","sponsor":"Hanmi Pharmaceutical Company Limited","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02444819/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/"}],"company":[{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/"}]}}